BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1193 related articles for article (PubMed ID: 8811494)

  • 1. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
    Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
    Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
    Cormier JN; Abati A; Fetsch P; Hijazi YM; Rosenberg SA; Marincola FM; Topalian SL
    J Immunother; 1998 Jan; 21(1):27-31. PubMed ID: 9456433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
    Mocellin S; Fetsch P; Abati A; Phan GQ; Wang E; Provenzano M; Stroncek D; Rosenberg SA; Marincola FM
    J Immunother; 2001; 24(6):447-58. PubMed ID: 11759068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
    de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
    Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
    Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
    J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.
    de Vries TJ; Trancikova D; Ruiter DJ; van Muijen GN
    Br J Cancer; 1998 Nov; 78(9):1156-61. PubMed ID: 9820172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look.
    Fetsch PA; Steinberg SM; Riker AI; Marincola FM; Abati A
    Cancer; 2001 Dec; 93(6):409-14. PubMed ID: 11748581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of MART-1 in primary and metastatic melanoma lesions.
    Kageshita T; Kawakami Y; Hirai S; Ono T
    J Immunother; 1997 Nov; 20(6):460-5. PubMed ID: 9409451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
    Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
    J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
    Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
    Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
    Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
    Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
    Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.
    Wagner SN; Wagner C; Schultewolter T; Goos M
    Cancer Immunol Immunother; 1997 Jun; 44(4):239-47. PubMed ID: 9222283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of melanoma-associated antigens in melanoma cell cultures.
    Urosevic M; Braun B; Willers J; Burg G; Dummer R
    Exp Dermatol; 2005 Jul; 14(7):491-7. PubMed ID: 15946236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
    Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
    J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.
    Trefzer U; Hofmann M; Reinke S; Guo YJ; Audring H; Spagnoli G; Sterry W
    Melanoma Res; 2006 Apr; 16(2):137-45. PubMed ID: 16567969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.